bcrp - publications

Predict more bcrp - ligand interactions now!


1. Int J Cancer. 2012 Apr 2. doi: 10.1002/ijc.27567. [Epub ahead of print]

A comprehensive study of polymorphisms in ABCB1, ABCC2 and ABCG2 and lung cancer
chemotherapy response and prognosis.

Campa D, Müller P, Edler L, Knoefel L, Barale R, Heussel CP, Thomas M, Canzian F,
Risch A.

Genomic Epidemiology Group, German Cancer Research Center (DKFZ), Heidelberg,
Germany; Department of Biology, University of Pisa, Pisa, Italy.

ATP-binding cassette (ABC) transporter expression and genetic heterogeneity have
been implicated in response to anticancer therapy. This study characterized
genetic variability of the ABCB1 (also known as MDR1), ABCC2 (MRP2) and ABCG2
(BCRP) genes, which are key players in the metabolism of many chemotherapeutic
agents including those used in the treatment of lung cancer. We genotyped 53
polymorphisms in the candidate genes in genomic DNA samples of 171 cases of small
cell lung carcinoma (SCLC) and 206 cases of non-small cell lung carcinoma
(NSCLC), and studied their impact on early response to chemotherapy, progression
free survival and overall survival. SNP rs717620 in ABCC2 was moderately
associated with a poor response to chemotherapy but strongly with shorter
progression free survival and overall survival in SCLC but not NSCLC patients,
indicating that ABCC2 genetic variation is an important factor in SCLC survival
after chemotherapy. © 2012 Wiley-Liss, Inc.

Copyright © 2012 UICC.

PMID: 22473764 [PubMed - as supplied by publisher]